Arvinas (NASDAQ: ARVN) insider transactions
In the twelve months to 10 November 2026, executives and directors of Arvinas reported 23 open-market sales of 126,258 shares ($1.4m) and 1 open-market purchase of 20,000 shares ($268,000), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 9 November 2026 | Loomis David K | VP, Chief Accounting Officer | Open-market sale, 10b5-1 plan | −232 | $6.36 | 39,961 | Form 4 |
| 24 June 2026 | Bain Linda | Director | Grant or award | +15,527 | — | 41,572 | Form 4 |
| 24 June 2026 | Cunningham Everett | Director | Grant or award | +15,527 | — | 41,572 | Form 4 |
| 24 June 2026 | Kennedy Edward Moore Jr. | Director | Grant or award | +15,527 | — | 54,957 | Form 4 |
| 24 June 2026 | Morrison Briggs | Director | Grant or award | +15,527 | — | 111,548 | Form 4 |
| 24 June 2026 | Norwalk Leslie V | Director | Grant or award | +15,527 | — | 41,572 | Form 4 |
| 24 June 2026 | Smaldone Alsup Laurie | Director | Grant or award | +15,527 | — | 41,572 | Form 4 |
| 24 June 2026 | Saik Andrew | Chief Financial Officer | Open-market sale, 10b5-1 plan | −5,696 | $8.16 | 187,432 | Form 4 |
| 17 June 2026 | Cacace Angela M | Chief Scientific Officer | Open-market sale, 10b5-1 plan | −2,576 | $7.60 | 180,390 | Form 4 |
| 21 May 2026 | Teel Randy | President and CEO | Open-market sale | −2,209 | $9.04 | 285,009 | Form 4 |
| 11 May 2026 | Teel Randy | President and CEO | Open-market sale | −9,657 | $9.94 | 287,218 | Form 4 |
| 11 May 2026 | Berkowitz Noah | Chief Medical Officer | Open-market sale | −11,108 | $9.94 | 191,395 | Form 4 |
| 11 May 2026 | Cacace Angela M | Chief Scientific Officer | Open-market sale | −9,657 | $9.94 | 182,966 | Form 4 |
| 11 May 2026 | Loomis David K | VP, Chief Accounting Officer | Open-market sale | −1,919 | $9.94 | 40,193 | Form 4 |
| 11 May 2026 | Saik Andrew | Chief Financial Officer | Open-market sale | −11,139 | $9.94 | 193,128 | Form 4 |
| 18 March 2026 | Berkowitz Noah | Chief Medical Officer | Open-market sale | −6,435 | $11.10 | 202,503 | Form 4 |
| 6 March 2026 | Morrison Briggs | Director | Open-market purchase | +20,000 | $13.40 | 96,021 | Form 4 |
| 27 February 2026 | Houston John G | Director | Open-market sale | −4,688 | $13.24 | 1,152,792 | Form 4 |
| 27 February 2026 | Houston John G | Director | Open-market sale | −18,822 | $13.24 | 1,133,970 | Form 4 |
| 27 February 2026 | Houston John G | Director | Open-market sale | −11,787 | $13.14 | 1,122,183 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Arvinas page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.